Login to Your Account

Seattle Genetics Gets ODAC Vote, Another Trial Looms

By Mari Serebrov

Friday, July 15, 2011
WASHINGTON – An advisory committee voted unanimously for accelerated approval for two lymphoma indications for Seattle Genetics Inc.'s Adcetris, but the company has its work cut out for it if it hopes to get FDA approval by its Aug. 30 PDUFA date.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription